肺泰胶囊维持治疗对中晚期非小细胞肺癌无进展生存期的影响

Effect of maintenance therapy with feitai capsules in patients with advanced non-small cell lung cancer

目的:观察中药复方肺泰胶囊维持治疗对中晚期非小细胞肺癌(NSCLC)无进展生存期的影响。方法:按标准入选中晚期NSCLC患者62例,随机分为治疗组和对照组各31例,治疗组给予肺泰胶囊维持治疗,对照组随访观察。随访统计无疾病进展生存期(PFS)。组间临床特征采用方差分析,PFS比较采用Kaplan-Meier分析。结果:入组62例,2例出组,60例可评价疗效,治疗前两组基线资料分布均衡(P>0.05)。治疗组和对照组PFS分别为6.23个月和4.67个月(P=0.048)。结论:中药复方肺泰胶囊维持治疗可延长中晚期NSCLC患者无进展生存期。

Objective：To evaluate the progression-free survival of Traditional Chinese Medicine compound feitai capsules with maintenance therapy in patients with advanced non-small cell lung cancer.Methods：Sixty-two patients with more advanced or advanced NSCLC were randomly assigned to two groups,the 31 patients in the treatment group received feitai capsules,and the other 31 patients in the control group with continual observation.Progression-free survival were evaluated regularly by Kaplan-Meier analysis,variations of the clinical characteristic were assessed by the analysis of ANOVA.Results：Sixty-two patients were included in the trial,with 2 patients excluded.Baseline charcaters between groups were not significant difference（P〉0.05）.In the treatment group,progression-free survival extended about 1.5 months（P=0.048）.Conclusion：Maintenance treatment by feitai capsules can effectively prolong progression-free survival in patients with advanced non-small cell lung cancer.